REFERENCES
1. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7-25.
2. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980-9.
3. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
4. Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
5. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836-46.
6. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19.
7. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:88-99.
8. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25:5815-24.
9. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
10. Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol 2014;77:695-703.
11. Fan P, Jordan VC. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids 2014;90:44-52.
12. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
13. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10.
14. Martin LA, Ghazoui Z, Weigel MT, Pancholi S, Dunbier A, et al. An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 2011;76:772-6.
15. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
16. Jordan VC, Curpan R, Maximov PY. Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. J Natl Cancer Inst 2015;107:djv075.
17. Frasor J, El-Shennawy L, Stender JD, Kastrati I. NF-κB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol 2015;418:235-9.
18. Fan P, Tyagi AK, Agboke FA, Mathur R, Pokharel N, et al. Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discov 2018;4:15.
21. Murray JI, West NR, Murphy LC, Watson PH. Intratumoural inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 2015;22:R51-67.
22. Fan P, Jordan VC. How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells? Cell Death Dis 2018;9:842.
23. Fan P, Abderrahman B, Chai TS, Yerrum S, Jordan VC. Targeting peroxisome proliferator-activated receptor γ to increase estrogen-induced apoptosis in estrogen-deprived breast cancer cells. Mol Cancer Ther 2018;17:2732-45.
24. Song RX, Mor G, Naftolin F, McPherson RA, Song J, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol. J Natl Cancer Inst 2001;93:1714-23.
25. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-59.
26. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-36.
27. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95:1586-97.
28. Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 2015;22:R1-31.
29. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, et al. Lower-dose vs. high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774-80.
30. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007;67:1352-60.
31. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, et al. Bidirectional cross talk between ERalpha and EGFR signaling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006;96:131-46.
32. Fan P, Agboke FA, Cunliffe HE, Ramos P, Jordan VC. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer 2014;50:2866-76.
33. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011;25:516-28.
34. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011;17:1147-59.
35. Verma S, Miles D, Gianni L, Krop IE, Welslau M, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
36. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
37. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-5.
38. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
39. Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, et al. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. Breast Cancer Res Treat 2019;175:149-63.
40. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74.
41. Zhao Y, Planas-Silva MD. Mislocalizaion of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity. Cancer Lett 2009;275:204-12.
42. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, et al. Dual targeting of SRC and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115:57-67.
43. Fan P, Cunliffe HE, Griffith OL, Agboke FA, Ramos P, et al. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. Eur J Cancer 2014;50:2877-86.
44. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
45. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989;49:4090-3.
46. Fan P, Agboke FA, McDaniel RE, Sweeney EE, Zou X, et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer 2014;50:457-68.
47. Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, et al. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol 2007;30:509-20.
48. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003;81:81-93.
49. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33.
50. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012;72:3372-80.
51. Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, et al. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Mol Cancer Res 2016;14:470-81.
52. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
53. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000;92:1926-34.
54. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999;5:251-6.
56. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008;6:1630-8.
57. Fan P, Cunliffe HE, Maximov PY, Agboke FA, McDaniel RE, et al. Integration of downstream signals of insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer cells. Mol Cancer Res 2015;13:1367-76.
58. Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene 2017;36:2286-96.
59. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
60. Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. Clin Cancer Res 2015;22:1130-7.
61. Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun 2017;8:1865.
62. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446-51.
63. Toy W, Shen Y, Won H, Green B, Sakr RA, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
64. Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995;9:1053-63.
65. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994;31:129-38.
66. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013;73:6856-64.
67. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014;20:1757-67.
68. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer research 1997;57:1244-9.
69. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 2016;7:11579.
70. Arnold SF, Obourn JD, Jaffe H, Notides AC. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 1995;9:24-33.
71. Jin K, Park S, Teo WW, Korangath P, Cho SS, et al. HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov 2015;5:944-59.
72. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
74. Mao C, Livezey M, Kim JE, Shapiro DJ. Antiestrogen resistant cell lines expressing estrogen receptor α mutations upregulate the unfolded protein response and are killed by BHPI. Sci Rep 2016;6:34753.
75. Andruska ND, Zheng X, Yang X, Mao C, Cherian MM, et al. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. Proc Natl Acad Sci U S A 2015;112:4737-42.
76. Zhao Y, Laws MJ, Guillen VS, Ziegler Y, Min J, et al. Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res 2017;77:5602-13.
77. Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem 2015;58:4888-904.
78. De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, et al. Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetra hydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. J Med Chem 2015;58:8128-40.
79. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
80. Torres MJ, Kew KA, Ryan TE, Pennington ER, Lin CT, et al. 17β-Estradiol directly lowers mitochondrial membrane microviscosity and improves bioenergetic function in skeletal muscle. Cell Metab 2018;27:167-79.
81. Gupte AA, Pownall HJ, Hamilton DJ. Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res 2015;2015:916585.
82. Maniu A, Aberdeen GW, Lynch TJ, Nadler JL, Kim SO, et al. Estrogen deprivation in primate pregnancy leads to insulin resistance in offspring. J Endocrinol 2016;230:171-83.
83. Misso ML, Jang C, Adams J, Tran J, Murata Y, et al. Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas 2005;51:299-306.
84. Ribas R, Ghazoui Z, Gao Q, Pancholi S, Rani A, et al. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. Breast Cancer Res 2014;16:447.
85. Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, et al. Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell 2017;65:1122-35.
86. Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, et al. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 2018;20:106.
87. Skildum A, Dornfeld K, Wallace K. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. Breast Cancer Res Treat 2011;129:785-97.
88. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2007;14:293-303.
90. Liao X, Zhang R, Lu Y, Prosdocimo DA, Sangwung P, et al. Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J Clin Invest 2015;125:3461-76.
91. Weigt C, Hertrampf T, Kluxen FM, Flenker U, Hülsemann F, et al. Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats. Mol Cell Endocrinol 2013;377:147-58.
92. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, et al. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 2006;13:233-50.
93. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res 2009;69:687-94.
94. Talbert DR, Allred CD, Zaytseva YY, Kilgore MW. Transactivation of ERalpha by rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 2008;108:23-33.
95. Llopis J, Westin S, Ricote M, Wang Z, Cho CY, et al. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc Natl Acad Sci USA 2000;97:4363-8.
96. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011;12:715-23.
97. Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Targeting ribonucleotide reductase M2 and NF-κB activation with Didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther 2015;14:2411-21.
98. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, et al. Enhanced NF-κB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;14:59-74.
99. Baumgarten SC, Frasor J. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 2012;26:360-71.
100. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615-29.
101. Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, et al. The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res 2012;14:212.
102. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006;25:6868-86.
103. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, et al. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006;21:555-64.
104. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
105. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
106. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91.
107. Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, et al. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A 2009;106:22504-9.
108. Franco HL, Nagari A, Kraus WL. TNFα signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. Mol Cell 2015;58:21-34.
109. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481:389-93.
110. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal hysterectomy: extended follow-up of the Women’s Health Initiative Randomised Trial. Lancet Oncol 2012;13:476-86.
111. Sweeney EE, Fan P, Jordan VC. Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women’s health initiative study. Cancer Res 2014;74:7060-8.
112. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
113. De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010;10:497-504.
114. Oh KS, Patel H, Gottschalk RA, Lee WS, Baek S, et al. Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. Immunity 2017;47:298-309.
115. Vandevyver S, Dejager L, Van Bogaert T, Kleyman A, Liu Y, et al. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest 2012;122:2130-40.
116. Miller WR, Larionov A. Molecular effects of oestrogen deprivation in breast cancer. Mol Cell Endocrinol 2011;340:127-36.
117. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A 2011;108:18879-86.
118. Fan P, Griffith OL, Agboke FA, Anur P, Zou X, et al. c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res 2013;73:4510-20.
119. Sweeney EE, Fan P, Jordan VC. Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells. Int J Oncol 2014;44:1529-38.
120. Ferrara P, Andermarcher E, Bossis G, Acquaviva C, Brockly F, et al. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 2003;22:1461-74.
121. Fan P, Siwak DR, Abderrahman B, Agboke FA, Yerrum S, et al. Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-induced Apoptosis in Estrogen-deprived Breast Cancer Cells. Mol Cancer Ther. Forthcoming 2019.
122. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008;454:455-62.
123. Zaytseva YY, Wang X, Southard RC, Wallis NK, Kilgore MW. Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer 2008;7:90.
124. Wang X, Sun Y, Wong J, Conklin DS. PPARγ maintains ERBB2-positive breast cancer stem cells. Oncogene 2013;32:5512-21.
125. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-91.
126. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107:8788-93.
127. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013;12:703-19.
